BRPI1013956B8 - método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão - Google Patents

método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão

Info

Publication number
BRPI1013956B8
BRPI1013956B8 BRPI1013956A BRPI1013956A BRPI1013956B8 BR PI1013956 B8 BRPI1013956 B8 BR PI1013956B8 BR PI1013956 A BRPI1013956 A BR PI1013956A BR PI1013956 A BRPI1013956 A BR PI1013956A BR PI1013956 B8 BRPI1013956 B8 BR PI1013956B8
Authority
BR
Brazil
Prior art keywords
spray dried
dried particles
isolating
oxalate
composition
Prior art date
Application number
BRPI1013956A
Other languages
English (en)
Inventor
Blake Cowley Aaron
Gölander Carl-Gustaf
Sidhu Harmeet
Li Qingshan
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/497,275 external-priority patent/US8431122B2/en
Priority claimed from EP09164430.2A external-priority patent/EP2270138B1/en
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of BRPI1013956A2 publication Critical patent/BRPI1013956A2/pt
Publication of BRPI1013956B1 publication Critical patent/BRPI1013956B1/pt
Publication of BRPI1013956B8 publication Critical patent/BRPI1013956B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/13Transferases (2.) transferring sulfur containing groups (2.8)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0008Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, método para reduzir a absorção de oxalato. a presente invenção compreende métodos e composições para a redução de oxalato em humanos, e métodos para a purificação e isolamento de proteínas de enzima de redução de oxalato recombinantes. a invenção fornece métodos e composições para a dispensação de enzimas que reduzem oxalato em composições de partícula. as composições da presente invenção são adequadas nos métodos de tratamento ou prevenção de condições relacionadas ao oxalato.
BRPI1013956A 2009-07-02 2010-07-01 método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão BRPI1013956B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/497275 2009-07-02
US12/497,275 US8431122B2 (en) 2009-07-02 2009-07-02 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
EP09164430.2A EP2270138B1 (en) 2009-07-02 2009-07-02 Purification and isolation of recombinant oxalate degrading enzymes
EP09164430.2 2009-07-02
PCT/EP2010/003864 WO2011000523A1 (en) 2009-07-02 2010-07-01 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Publications (3)

Publication Number Publication Date
BRPI1013956A2 BRPI1013956A2 (pt) 2019-04-09
BRPI1013956B1 BRPI1013956B1 (pt) 2021-04-06
BRPI1013956B8 true BRPI1013956B8 (pt) 2021-05-25

Family

ID=43028177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013956A BRPI1013956B8 (pt) 2009-07-02 2010-07-01 método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão

Country Status (16)

Country Link
US (1) US20120189604A1 (pt)
EP (1) EP2449098B1 (pt)
JP (2) JP2012531186A (pt)
CN (2) CN104805067A (pt)
BR (1) BRPI1013956B8 (pt)
CA (2) CA3012811A1 (pt)
DK (1) DK2449098T3 (pt)
ES (1) ES2617917T3 (pt)
HK (1) HK1210805A1 (pt)
HU (1) HUE030905T2 (pt)
IL (1) IL216873A (pt)
IN (1) IN2012DN00592A (pt)
LT (1) LT2449098T (pt)
PL (1) PL2449098T3 (pt)
PT (1) PT2449098T (pt)
WO (1) WO2011000523A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
US9714456B2 (en) * 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
CN103540569A (zh) * 2013-06-05 2014-01-29 黄虹寓 结石酶及其制备方法
CA2913476A1 (en) * 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
CN107299089B (zh) * 2014-12-22 2019-09-17 武汉康复得生物科技股份有限公司 一种在生理pH条件下有活力的草酸氧化酶及其应用
CN116124853B (zh) * 2022-11-07 2024-01-16 东北农业大学 一种检测草酸的电化学生物传感器、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
WO2004018634A2 (en) * 2002-08-20 2004-03-04 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
EP1962873B1 (en) * 2005-12-14 2013-05-29 OxThera, Inc., Pharmaceutical compositions comprising oxalate-reducing bacteria
CN104013581A (zh) * 2005-12-16 2014-09-03 奥克斯赛拉公司 用于减少草酸和/或其盐的组合物和方法
CN103272225B (zh) * 2006-08-02 2018-05-22 味之素阿尔西亚有限公司 结晶化的草酸脱羧酶和使用方法

Also Published As

Publication number Publication date
IL216873A0 (en) 2012-02-29
BRPI1013956A2 (pt) 2019-04-09
EP2449098B1 (en) 2016-12-07
JP2016121138A (ja) 2016-07-07
EP2449098A1 (en) 2012-05-09
BRPI1013956B1 (pt) 2021-04-06
PL2449098T3 (pl) 2017-06-30
JP6220845B2 (ja) 2017-10-25
CA2767039A1 (en) 2011-01-06
DK2449098T3 (en) 2017-03-06
IN2012DN00592A (pt) 2015-06-12
JP2012531186A (ja) 2012-12-10
CN102597225B (zh) 2015-04-29
CN104805067A (zh) 2015-07-29
PT2449098T (pt) 2017-03-10
CN102597225A (zh) 2012-07-18
HK1210805A1 (en) 2016-05-06
WO2011000523A1 (en) 2011-01-06
ES2617917T3 (es) 2017-06-20
HUE030905T2 (en) 2017-06-28
CA2767039C (en) 2018-09-04
CA3012811A1 (en) 2011-01-06
LT2449098T (lt) 2017-05-25
US20120189604A1 (en) 2012-07-26
IL216873A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
BRPI1013956B8 (pt) método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão
WO2010056981A3 (en) Methods and compositions for regulating iron homeostasis by modulation bmp-6
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056021A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2011106766A3 (en) Modified proteins and methods of making and using same
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2007056220A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2010101627A3 (en) Methods and systems for treatment and/or diagnosis
MX343087B (es) Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
BRPI0815395A2 (pt) Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2008133722A3 (en) Anti human sclerostin antibodies
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
WO2011097381A8 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
WO2008036932A3 (en) Compositions and methods comprising boswellia species
BR112012012460A2 (pt) "método de liofilização, composições e kits".
EP2380591A3 (en) Vaccine peptide combinations against cat allergy
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2012010974A8 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
BR112015000731A2 (pt) método para equiparação de cor de revestimento, sistema automático para equiparação de cor e sistema para dispensar uma composição de revestimento
BR112012027531A2 (pt) método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: OXTHERA INTELLECTUAL PROPERTY AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2677 DE 26-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.